# A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

> **NCT07390383** · PHASE2 · RECRUITING · sponsor: **Nanjing Leads Biolabs Co.,Ltd** · enrollment: 110 (estimated)

## Conditions studied

- Advanced Solid Tumour

## Interventions

- **DRUG:** LBL-024 for Injection
- **DRUG:** Capecitabine tablets
- **DRUG:** Tislelizumab Injection
- **DRUG:** Oxaliplatin injection

## Key facts

- **NCT ID:** NCT07390383
- **Lead sponsor:** Nanjing Leads Biolabs Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-13
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07390383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07390383, "A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07390383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*